Immune checkpoint inhibitors for cancer and venous thromboembolic events

Source: docwirenews, October 2021

BACKGROUND: Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. There are limited data on the risk for developing venous thromboembolism (VTE) among patients on an ICI.

READ THE ORIGINAL FULL ARTICLE